Gabapentin Weaning Guidelines

Indications for Weaning

Gabapentin should be weaned gradually rather than abruptly discontinued to prevent withdrawal symptoms, especially in patients who have been taking it for longer than 14 days or at high doses, as recommended by the American Academy of Pediatrics 1, 2
Gabapentin weaning is recommended after completing treatment for unexplained chronic cough, typically reassessing after 6 months of therapy, according to the American College of Chest Physicians 3, 4, 5
The American College of Cardiology suggests that gabapentin weaning is indicated when the risk-benefit profile is no longer favorable, such as excessive side effects with minimal benefit 4, 6
The Centers for Disease Control and Prevention recommend weaning gabapentin when transitioning to alternative medications for pain management 7

Duration of therapy longer than 14 days is considered high risk for withdrawal symptoms, as stated by the American Academy of Pediatrics 1, 2
Duration of therapy between 7-14 days is considered moderate risk for withdrawal symptoms, according to the American Academy of Pediatrics 1, 2
Concurrent use of other central nervous system depressants increases the risk of withdrawal symptoms, as noted by the Centers for Disease Control and Prevention 7

For patients taking gabapentin for less than 7 days, the American Academy of Pediatrics recommends that they can usually discontinue quickly without formal tapering 1, 2
For patients taking gabapentin for 7-14 days, the recommended taper is to reduce by 300 mg every 1-2 days, with monitoring for withdrawal symptoms, as suggested by the American Academy of Pediatrics 1, 2
For patients taking gabapentin for longer than 14 days, the initial taper should be a 10-20% reduction of the original dose every 24-48 hours, according to the American Academy of Pediatrics 1, 2
For high-dose or long-term use, a slower taper may be required, approximately 10% reduction per week or even per month, as recommended by the Centers for Disease Control and Prevention 7

The American Academy of Pediatrics suggests that clonidine may help manage autonomic withdrawal symptoms 1, 2
Non-pharmacological approaches for insomnia and anxiety, as well as behavioral interventions to address psychological dependence, are recommended by the American Academy of Pediatrics 2
Temporary symptomatic treatment for breakthrough pain may be indicated, as noted by the American Academy of Pediatrics 2
The Centers for Disease Control and Prevention recommend pausing the taper temporarily when withdrawal symptoms occur and resuming at a slower rate when symptoms subside 7